Germline testing among ovarian cancer patients using an integrated clinical pathway dashboard at Kaiser Permanente, Northern California

被引：0
|
作者：
Kavecansky, Juraj [1 ]
Duffens, Ali [1 ]
Brenman, Leslie Manace [1 ]
Garcia, Christine [1 ]
Sun, Hongxin [2 ]
机构：
[1] Kaiser Permanente Northern Calif, Walnut Creek, CA USA
[2] Permanente Med Grp Inc, TPMG Consulting Serv, Oakland, CA USA
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
10.1016/j.ygyno.2024.07.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1157
引用
收藏
页码：S148 / S149
页数：2
相关论文
共 47 条
  • [21] HRD Testing and BRCA1/2 Germline Testing in routine clinical Practice in Female Patients with primary Ovarian Cancer
    Holly, J.
    Harter, P.
    Ataseven, B.
    Moubarak, M.
    Schwameis, R.
    Heikaus, S.
    Concin, N.
    Rhiem, K.
    Denkert, C.
    Heitz, F.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (04) : E5 - E6
  • [22] Impact of universal germline testing on pathogenic/likely pathogenic variant frequency among breast cancer patients in Southern California
    Dzubnar, Jessica
    Wang, Yongzhe
    Aljaber, Dana
    Quinones, Christine
    Tseng, Jennifer
    Solomon, Ilana
    Gonzalez, Lorena
    Gray, Stacy
    Jones, Veronica
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [23] The impact of the COVID-19 pandemic shelter in place on glycemic control, blood pressure control, and body mass index among diabetic patients at Kaiser Permanente Northern California: a retrospective cohort study
    Yamamoto, Kyle
    Merchant, Maqdooda
    Bommireddi, Akshay
    Vu, Joseph
    Pursnani, Seema K.
    BMC PUBLIC HEALTH, 2025, 25 (01)
  • [24] Improving access to hereditary cancer genetic testing in diverse populations: Outcomes in over 33,000 patients tested by genetics and non-genetics providers in Kaiser Permanente Southern California
    Alvarado, Monica
    Hoffman, Trevor
    Haque, Reina
    Kershberg, Hilary
    Goff, John
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [25] Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing
    Ng, P. S.
    Wen, W. X.
    Fadlullah, M. Z. H.
    Yoon, S. Y.
    Lee, S. Y.
    Thong, M. K.
    Yip, C. H.
    Taib, N. A. Mohd
    Teo, S. H.
    CLINICAL GENETICS, 2016, 90 (04) : 315 - 323
  • [26] Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study
    Abdel-Razeq, Hikmat
    Al-Azzam, Khansa
    Elemian, Shatha
    Abu-Fares, Hala
    Abu Sheikha, Areej
    Bani Hani, Hira
    Bater, Rayan
    Sharaf, Baha'
    Heald, Brandie
    Esplin, Edward D.
    Nielsen, Sarah M.
    Alkyam, Mais
    Abujamous, Lama
    Al-Attary, Areej
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2023, 11 (04):
  • [27] SARS-CoV-2 Clinical Outcomes in Patients with Cancer in a Large Integrated Health Care System in Northern California
    Anantharaman, Archana
    Dusendang, Jennifer R.
    Schmittdiel, Julie A.
    Harzstark, Andrea L.
    ONCOLOGIST, 2021, 26 (03): : E500 - E504
  • [28] Germline mutation prevalence among US and non-US Hispanic patients undergoing genetic testing for breast and ovarian cancer predisposition
    Lincoln, Stephen E.
    Pineda-Alvarez, Daniel
    Michalski, Scott T.
    Yang, Shan
    Esplin, Edward D.
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients Clinical Testing with a Multigene Test Panel
    Kwong, Ava
    Shin, Vivian Y.
    Chen, Jiawei
    Cheuk, Isabella W. Y.
    Ho, Cecilia Y. S.
    Au, Chun H.
    Chan, Karen K. L.
    Ngan, Hextan Y. S.
    Chan, Tsun L.
    Ford, James M.
    Ma, Edmond S. K.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (04): : 544 - 554
  • [30] Automated data base screening of a population-based cohort of stage 1 colon cancer patients for eligibility in NSABP P-3, a polyp prevention study with celecoxib at Kaiser Permanente Northern California (KPNC).
    Somkin, C. P.
    Gross, R.
    Liu, H.
    Fehrenbacher, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 54S - 54S
12345